The care process of patient receiving CAR T-cell therapy: Guidelines from the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)

In Europe, two CAR T-cell products, tisagenledeucel (Kymriah (TM)) and axicobtagene ciloleucel (Yescarte (TM)), were approved in 2018. While these treatments ore available for use, allogeneic hematopoietic stem cell transplantation centers still need to set up a dedicated care process inspired by established procedures in the field. In order to determine necessary resources and actors, each step of the CAR T-cell care process must be planned in advance. This process, implemented by the center's coordinating nurse, should be able to be adopted to each center's needs. The purpose of this workshop is to provide the organizational basis for such a process so that each center wishing to set up CAR-T cell activity con do so effectively. After detailing the coordinating nurse's role, we explain each step of the care process and specify essential additional tests.